Second Allowance Covers Its Unique Insulin Administration Method

November 18, 2015 09:00 AM Eastern Standard Time


WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application directed toward a method of administering insulin proven to improve patient outcomes compared to antiquated paper protocols. The method entails selecting a precise subcutaneous insulin treatment for each patient based on blood glucose measurements and other patient information, and administering the selected treatment.

Ninety percent of study participants achieved target glucose within 3 weeks and achieved an average reduction in estimated A1C of 3.0%.

Waltham, MA — November 3, 2015 – Glytec,the pioneer and leader in providing innovative glucose management software solutions, announced today that Glucommander™, a component of the company’s eGMS® platform, achieved its 30-day primary efficacy endpoint in a study evaluating the average A1C reduction in an outpatient setting for persons with type 1 and type 2 diabetes.

According to study results, Glucommander was effective at titrating insulin doses and quickly achieving glucose control, with low rates of hypoglycemia, for 22 patients, regardless of the severity of their diabetes. The average starting A1C was 10.4% and the average estimated A1C (eA1C) at 30-days was 7.4%. A larger study looking at 3-month reduction in A1C will be published in the near future.

October 14, 2015 09:00 AM Eastern Daylight Time

WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering key aspects of the company’s core technology for diabetes management. The allowed claims are directed to a system for glycemic control of a diabetic patient that includes a smartphone-based diabetes mobile application, which will provide patients with real-time insulin dosing guidance, leveraging Glytec’s proprietary insulin titration technology.

October 20, 2015 09:00 AM Eastern Daylight Time

WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announced today that Hartford HealthCare will deploy the company’s eGlycemic Management System® (eGMS®) across its five hospitals. eGMS® enables providers, payers and patients to control glucose levels and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.

Hartford HealthCare (HHC), well known for quality, complex and innovative care, consists of Hartford Hospital, Backus Hospital, MidState Medical Center, The Hospital of Central Connecticut and Windham Hospital, as well as numerous clinics throughout Connecticut. Glytec’s unique eGMS® will help support HHC’s tradition of patient focus and quality of care by providing access to evidence-based, medical intelligence for patients requiring insulin therapy.

Study from Emory University published in Diabetes Care leverages Glytec’s Glucommander IV™ platform to evaluate the optimal level of glycemic control needed to improve outcomes

September 29, 2015 10:30 AM Eastern Daylight Time


WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative glucose management software solutions central to effective diabetes management, is pleased to share the results of the GLUCO-CABG trial(1) conducted by Emory University, which demonstrated intensive insulin therapy resulted in a reduction in post cardiac surgery complications. Hyperglycemia is common in patients undergoing cardiac surgery, reported in 60 – 90 percent of patients with a known history of diabetes and in more than half of patients without diabetes (2-3).

The randomized controlled trial, conducted leveraging Glytec’s Glucommander IV™, an FDA-cleared solution which establishes glycemic control via accurate, patient-specific insulin dosing, looked at a total of 302 patients after coronary artery bypass graft (CABG) surgery. Results demonstrated that providing more precise insulin dosing via the Glucommander IV™ led to improved glycemic control and a significant reduction in the rate of hypoglycemia, which is a common side effect of intensive insulin therapy in patients undergoing cardiac surgery.

Page 1 of 6